ALD-52

ALD-52
Clinical data
Other namesALD52; ALD; 1-Acetyl-N,N-diethyllysergamide; 1-Acetyl-LSD; 1A-LSD; N-Acetyl-LSD; Acetyl-LSD
Routes of
administration		Oral
Drug classSerotonergic psychedelic; Hallucinogen
Legal status
Legal status
  • AU: Unscheduled
  • BR: Class F2 (Prohibited psychotropics)
  • CA: Unscheduled
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
  • US: Unscheduled, could be prosecuted under the Federal Analogue Act.
  • Unscheduled in the most countries of the world, Illegal in France, Romania, Switzerland, Finland and Singapore
Identifiers
  • (6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H27N3O2
Molar mass365.477 g·mol−1
3D model (JSmol)
  • O=C(n1cc2c3c(C4=C[C@@H](C(=O)N(CC)CC)CN([C@@H]4C2)C)cccc13)C
  • InChI=1S/C22H27N3O2/c1-5-24(6-2)22(27)16-10-18-17-8-7-9-19-21(17)15(13-25(19)14(3)26)11-20(18)23(4)12-16/h7-10,13,16,20H,5-6,11-12H2,1-4H3/t16-,20-/m1/s1 Y
  • Key:FJOWXGYLIWJFCH-OXQOHEQNSA-N Y
  (verify)

ALD-52, also known as 1-acetyl-LSD (1A-LSD), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It has been reported to produce similar psychoactive effects as LSD, but its pharmacological effects on humans are poorly understood.

The drug is assumed to act as a prodrug to LSD in humans, and this has been substantiated in vitro.

ALD-52 was initially synthesized in 1957 by Albert Hofmann. The purported first confirmed detection of the substance on the illicit market occurred in April 2016.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.